^
    Back
    Association details:
    Biomarker:CD20 positive
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:EX103 (CD20 inhibitor, CD3 agonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASH 2023
    Title:

    EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma

    Published date:
    11/02/2023
    DOI:
    https://doi.org/10.1182/blood-2023-173486